MaxCyte
MXCT
80 hedge funds and large institutions have $670M invested in MaxCyte in 2021 Q3 according to their latest regulatory filings, with 80 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
54.28% more ownership
Funds ownership: 0% → 54.28% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$211M |
| 2 |
DCP
D1 Capital Partners
New York
|
+$52.9M |
| 3 |
VP
Vitruvian Partners
London,
United Kingdom
|
+$50.2M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$46.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.5M |
Top Sellers
MXCT Hedge Fund Activity: Q3 2021 in Review
80 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q3 2021, worth a combined $670M.
Buyers outnumbered sellers: 80 funds opened new MXCT positions and 0 closed out — a net gain of 80 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Casdin Capital, opening a new position worth an estimated $211M.
- 80 institutional investors held MaxCyte (MXCT) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $670M of MaxCyte stock for Q3 2021.
- 80 funds opened new MaxCyte positions in Q3 2021 and 0 closed out, a net change of +80 holders.
- The largest MaxCyte buyer in Q3 2021 was Casdin Capital, an estimated $211M added.
Based on aggregated 13F filings for Q3 2021.